CytomX Therapeutics Total Assets 2014-2022 | CTMX

CytomX Therapeutics total assets from 2014 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
CytomX Therapeutics Annual Total Assets
(Millions of US $)
2021 $339
2020 $359
2019 $341
2018 $457
2017 $398
2016 $199
2015 $197
2014 $73
2013 $14
CytomX Therapeutics Quarterly Total Assets
(Millions of US $)
2022-09-30 $226
2022-06-30 $260
2022-03-31 $297
2021-12-31 $339
2021-09-30 $371
2021-06-30 $402
2021-03-31 $434
2020-12-31 $359
2020-09-30 $375
2020-06-30 $402
2020-03-31 $437
2019-12-31 $341
2019-09-30 $373
2019-06-30 $405
2019-03-31 $445
2018-12-31 $457
2018-09-30 $483
2018-06-30 $377
2018-03-31 $376
2017-12-31 $398
2017-09-30 $387
2017-06-30 $352
2017-03-31 $178
2016-12-31 $199
2016-09-30 $193
2016-06-30 $207
2016-03-31 $192
2015-12-31 $197
2015-09-30 $125
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2013-12-31 $14
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.177B $0.070B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $151.446B 9.24
GSK (GSK) United Kingdom $72.652B 9.59
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.227B 19.16
Ginkgo Bioworks Holdings (DNA) United States $3.880B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.620B 24.32
Biohaven (BHVN) United States $1.283B 0.00
Emergent Biosolutions (EBS) United States $0.681B 5.35
ADC Therapeutics SA (ADCT) Switzerland $0.419B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.066B 0.00
SQZ Biotechnologies (SQZ) United States $0.023B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00